Cellectar Biosciences Inc (CLRB)

Currency in USD
2.3700
+0.0200(+0.85%)
Closed·
2.37000.0000(0.00%)
·

CLRB Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.57 / -0.48
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/-0.445--/0.000----Free Sign Up
2026/06-0.570/-0.4800.000/0.000-18.75%--Free Sign Up
2026/03-1.33/-0.2000.000/8.00M-565%-100%Free Sign Up
2025/120.650/-0.1420.000/0.000+559.04%--Free Sign Up
2025/09-1.41/-0.1390.000/0.000-917.32%--Free Sign Up
2025/06-3.39/-0.1300.000/0.000-2,507.69%--Free Sign Up
2025/03-4.30/-0.1900.000/0.000-2,163.16%--Free Sign Up
2024/12-2.10/-0.3500.000/0.000-500%--Free Sign Up
2024/09-0.400/-0.3300.000/0.000-21.21%--Free Sign Up
2024/06-5.40/-0.3000.000/0.000-1,700%--Free Sign Up

All numbers in USD

Cellectar Biosciences Inc Earnings Call Summary for Q2/2026

  • Cellectar posted Q2 2026 loss of $0.57/share, missing analyst estimates of $0.48, though shares rose 3.85% on stronger cash position of $34M.
  • Company secured financing providing $35M upfront with potential for $140M total capital through warrant tranches at $2.65 strike price.
  • Site activation began for confirmatory Phase III Waldenstrom's macroglobulinemia study; FDA submission planned mid-2027 with 6-month review expected.
  • Management targets 10-20 sites open with initial enrollment by submission; iopofosine showed 79.2% major response rate in post-BTK inhibitor cohort.
  • R&D spending surged 92% to $4.6M as CLR 125 triple-negative breast cancer program dosed first patients; initial data expected late 2026 or early 2027.
Last Updated: 2026-08-13, 09:32 a/m
Read Full Transcript

FAQ

What Is Cellectar Biosciences's Earnings Per Share (TTM)?

The Cellectar Biosciences EPS (TTM) is -3.7512.

When Is The Next Cellectar Biosciences Earnings Date?

Cellectar Biosciences will release its next earnings report on Oct 29, 2026.

What Is Cellectar Biosciences’s Revenue Forecasts For Upcoming Quarters?

Cellectar Biosciences’s revenue forecast is 0.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.